Acrivon Therapeutics Investor Relations Material
Latest events
Status Update
Acrivon Therapeutics
Q1 2025
14 May, 2025
Q4 2024
26 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Acrivon Therapeutics Inc
Access all reports
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines. Utilizing its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, the company advances drug candidates tailored to the predicted sensitivity of tumors to specific medicines. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Acrivon Therapeutics Inc
Status Update
Acrivon Therapeutics Inc
Status Update
Acrivon Therapeutics Inc
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
ACRV
Country
🇺🇸 United States